16 production sites on 5 continents.
Affiliates or offices in 77 countries.
Products marketed in more than 165 countries.
Approximately 41,400 employees (June 2017).
19% within research and development
Africa, Asia, Middle East & Oceania: 6,489
China (4,265) & Taiwan: 4,357
Europe (excl. HQ): 3,914
Japan (1,105) & Korea: 1,223
Latin America: 1,752
North America (US 5,992 & Canada 302): 6,294
|(includes all Novo Nordisk and NNE employees in the respective locations)
According to applicable law, only health care professionals are allowed to access product information on our site. Please find the information under Health Care Professionals.
For patient and disease information, including pens and needles, please look under Patients.
28,638 million Danish kroner
Sales by business segment
Diabetes and obesity care total:
23,770 million Danish kroner
4,868 million Danish kroner
Sales by region
North America Operations:
15,103 million Danish kroner
USA: 14,583 million Danish kroner
13,535 million Danish kroner
Region Europe: 5,355 million Danish kroner
Region AAMEO: 3,057 million Danish kroner
Region China: 2,608 million Danish kroner
Region Japan & Korea: 1,573 million Danish kroner
Region Latin America: 942 million Danish kroner
Novo Nordisk A/S
CVR nr. 24 25 67 90